Patents by Inventor Mark F. Bear

Mark F. Bear has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods For Treatment Of 16P11.2 Microdeletion Syndrome
    Publication number: 20190256491
    Abstract: Subjects that have a 16p11.2 microdeletion syndrome are treated by administering compositions that include mGluR inhibitors, including mGluR antagonists that include mGluR negative allosteric modulators. Administration of compositions employed in the methods of the invention can treat psychiatric, including neuropsychiatric disorders, cognitive impairments, attention, obesity, intellectual disability and seizure disorders.
    Type: Application
    Filed: February 19, 2019
    Publication date: August 22, 2019
    Inventors: Mark F. Bear, Di Tian
  • METHODS OF TREATING AUTISM WITH mGluR5 ANTAGONISTS
    Publication number: 20150359766
    Abstract: mGluR5 antagonists are used for the treatment of autism. The human treated by the methods of the invention can also have fragile X syndrome, epilepsy and anxiety.
    Type: Application
    Filed: January 26, 2015
    Publication date: December 17, 2015
    Inventors: Mark F. Bear, Kimberly M. Huber, Stephen T. Warren
  • Methods of treating autism
    Patent number: 9044443
    Abstract: Subjects having autism are treated with a composition that includes gamma-aminobutyric acid agonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen. The humans can be administered the GABA(B) agonist in a single dose or multiple doses.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: June 2, 2015
    Assignee: CLINICAL RESEARCH ASSOCIATES, LLC
    Inventors: Kathryn Roberts, Randall L. Carpenter, Mark F. Bear
  • Methods for Treatment of 16P11.2 Microdeletion Syndrome
    Publication number: 20150057315
    Abstract: Subjects that have a 16p11.2 microdeletion syndrome are treated by administering compositions that include mGluR inhibitors, including mGluR antagonists that include mGluR negative allosteric modulators. Administration of compositions employed in the methods of the invention can treat psychiatric, including neuropsychiatric disorders, cognitive impairments, attention, obesity, intellectual disability and seizure disorders.
    Type: Application
    Filed: October 23, 2014
    Publication date: February 26, 2015
    Inventors: Mark F. Bear, Di Tian
  • Methods for Treating Alzheimer's Disease
    Publication number: 20140194524
    Abstract: Cognitive impairments in humans with Alzheimer's disease are treated by administering a composition that includes an amphetamine compound. Memory, attention and executive function can be improved following administration of the amphetamine compound.
    Type: Application
    Filed: December 13, 2013
    Publication date: July 10, 2014
    Applicant: Cognition Pharmaceuticals, LLC
    Inventors: Mel H. Epstein, Kjesten A. Wiig, Mark F. Bear
  • Methods of Treating Autism
    Publication number: 20130261186
    Abstract: Subjects having autism are treated with a composition that includes gamma-aminobutyric acid agonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen. The humans can be administered the GABA(B) agonist in a single dose or multiple doses.
    Type: Application
    Filed: June 7, 2013
    Publication date: October 3, 2013
    Applicant: Seaside Therapeutics, Inc.
    Inventors: Kathryn Roberts, Randall L. Carpenter, Mark F. Bear
  • METHODS FOR TREATING ALZHEIMER'S DISEASE
    Publication number: 20130231395
    Abstract: Cognitive impairments in humans with Alzheimer's disease are treated by administering a composition that includes an amphetamine compound. Memory, attention and executive function can be improved following administration of the amphetamine compound.
    Type: Application
    Filed: April 18, 2013
    Publication date: September 5, 2013
    Applicant: Cognition Pharmaceuticals, LLC
    Inventors: Mel H. Epstein, Kjesten A. Wiig, Mark F. Bear
  • Methods of Treating Autism
    Publication number: 20130012587
    Abstract: Subjects having autism are treated with a composition that includes gamma-aminobutyric acid agonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen.
    Type: Application
    Filed: September 13, 2012
    Publication date: January 10, 2013
    Applicant: Seaside Therapeutics, Inc.
    Inventors: Kathryn Roberts, Randall L. Carpenter, Mark F. Bear
  • Methods of Treating Fragile X Syndrome
    Publication number: 20130012586
    Abstract: Subjects having fragile X syndrome are treated with a composition that includes gamma-aminobutyric acid agonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen, including racemic and R-baclofen.
    Type: Application
    Filed: September 13, 2012
    Publication date: January 10, 2013
    Applicant: Seaside Therapeutics, Inc.
    Inventors: Kathryn Roberts, Randall L. Carpenter, Mark F. Bear
  • METHODS OF TREATING ELEVATIONS IN MTOR SIGNALING
    Publication number: 20120264784
    Abstract: Subjects having elevated signaling of a mammalian target of rapamycin (mTOR) are treated with compositions that include at least one compound that activates a Group 1 mGluR. In an embodiment, the subject has tuberous sclerosis complex (TSC). In an embodiment, the compound is a Group 1 mGluR agonist. In another embodiment, the compound is a Group 1 mGluR positive allosteric modulator.
    Type: Application
    Filed: April 25, 2012
    Publication date: October 18, 2012
    Inventors: Mark F. Bear, Benjamin David Auerbach
  • Methods of treating autism
    Patent number: 8278276
    Abstract: Subjects having autism are treated with a composition that includes gamma-aminobutyric acid agonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen.
    Type: Grant
    Filed: January 31, 2012
    Date of Patent: October 2, 2012
    Assignee: Seaside Therapeutics, Inc.
    Inventors: Kathryn Roberts, Randall L. Carpenter, Mark F. Bear
  • Methods of treating fragile X syndrome
    Patent number: 8273715
    Abstract: Subjects having fragile X syndrome are treated with a composition that includes gamma-aminobutyric acid agonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen, including racemic and R-baclofen.
    Type: Grant
    Filed: January 31, 2012
    Date of Patent: September 25, 2012
    Assignee: Seaside Therapeutics, Inc.
    Inventors: Kathryn Roberts, Randall L. Carpenter, Mark F. Bear
  • METHODS FOR TREATING ALZHEIMER'S DISEASE
    Publication number: 20120142785
    Abstract: Alzheimer's disease is treated with an amphetamine compound. In one embodiment, the method includes administering an l-amphetamine compound. In another embodiment, the method includes administering an l-methamphetamine compound.
    Type: Application
    Filed: January 10, 2012
    Publication date: June 7, 2012
    Applicant: Cognition Pharmaceuticals LLC
    Inventors: Mel H. Epstein, Kjesten A. Wiig, Mark F. Bear
  • METHODS OF TREATING AUTISM
    Publication number: 20120129940
    Abstract: Subjects having autism are treated with a composition that includes gamma-aminobutyric acid agonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen.
    Type: Application
    Filed: January 31, 2012
    Publication date: May 24, 2012
    Applicant: Seaside Therapeutics, Inc.
    Inventors: Kathryn Roberts, Randall L. Carpenter, Mark F. Bear
  • Methods of Treating Fragile X Syndrome
    Publication number: 20120122986
    Abstract: Subjects having fragile X syndrome are treated with a composition that includes gamma-aminobutyric acid agonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen, including racemic and R-baclofen.
    Type: Application
    Filed: January 31, 2012
    Publication date: May 17, 2012
    Applicant: Seaside Therapeutics, Inc.
    Inventors: Kathryn Roberts, Randall L. Carpenter, Mark F. Bear
  • Methods of treating fragile X syndrome and autism
    Patent number: 8143311
    Abstract: Subjects having autism are treated with a composition that includes gamma-aminobutyric acid agonists. Subjects having fragile X syndrome are treated with M1 muscarinic receptor antagonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen. GABA(B) agonists can be used in combination with Group I mGluR antagonists and M1 muscarinic receptor antagonists in methods of treating humans.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: March 27, 2012
    Assignee: Seaside Therapeutics, Inc.
    Inventors: Kathryn Roberts, Randall L. Carpenter, Mark F. Bear
  • Methods of Treating Disorders with Group I mGluR Antagonists
    Publication number: 20100210542
    Abstract: mGluR5 antagonists are used for the treatment and prevention of disorders, including Fragile X, autism, mental retardation, schizophrenia and Down's Syndrome. The methods of the invention can be used to treat epilepsy and anxiety in a human having Fragile X syndrome, autism, mental retardation, schizophrenia and Down's Syndrome.
    Type: Application
    Filed: January 15, 2010
    Publication date: August 19, 2010
    Inventors: Mark F. Bear, Kimberly M. Huber, Stephen T. Warren
  • Methods of treating mental retardation, down's syndrome, fragile X syndrome and autism
    Publication number: 20100029770
    Abstract: Subjects having at least one condition selected from the group consisting of mental retardation, Down's syndrome, fragile X syndrome and autism are treated with a composition that includes gamma-aminobutyric acid agonists and/or M1 muscarinic receptor antagonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen. GABA(B) agonists can be used in combination with Group I mGluR antagonists and M1 muscarinic receptor antagonists in methods of treating humans.
    Type: Application
    Filed: May 14, 2009
    Publication date: February 4, 2010
    Applicant: SeaSide Therapeutics, LLC
    Inventors: Kathryn Roberts, Randall L. Carpenter, Mark F. Bear
  • Methods of treating disorders with Group I mGluR antagonists
    Patent number: 7648993
    Abstract: mGluR5 antagonists are used for the treatment and prevention of disorders, including Fragile X, autism, mental retardation, schizophrenia and Down's Syndrome. The methods of the invention can be used to treat epilepsy and anxiety in a human having Fragile X syndrome, autism, mental retardation, schizophrenia and Down's Syndrome.
    Type: Grant
    Filed: December 17, 2004
    Date of Patent: January 19, 2010
    Assignees: Brown University, Emory University
    Inventors: Mark F. Bear, Kimberly M. Huber, Stephen T. Warren
  • Methods of treating disorders with Group I mGluR antagonists
    Patent number: 6916821
    Abstract: mGluR5 antagonists are used for the treatment and prevention of disorders, including Fragile X, autism, mental retardation, schizophrenia and Down's Syndrome. The methods of the invention can be used to treat epilepsy and anxiety in a human having Fragile X syndrome, autism, mental retardation, schizophrenia and Down's Syndrome.
    Type: Grant
    Filed: April 4, 2003
    Date of Patent: July 12, 2005
    Assignees: Brown University, Emory University
    Inventors: Mark F. Bear, Kimberly M. Huber, Stephen T. Warren